Cortagen is a synthetic short-chain peptide developed at the St. Petersburg Institute of Bioregulation and Gerontology under Vladimir Khavinson — derived by directed synthesis from the natural brain-cortex peptide preparation Cortexin. It is part of the broader Khavinson bioregulators family and has been studied more substantively than several of its siblings, including human-tissue work on peripheral nerve recovery. This monograph lays out the chemical identity, the Khavinson framework as it applies to neural tissue, the published research record, and how the compound relates to Cortexin and other Khavinson neural peptides.
Chemical identity and structure.
Cortagen is a tetrapeptide with the sequence Ala-Glu-Asp-Pro (alanine-glutamic acid-aspartic acid-proline). The sequence was obtained by directed synthesis based on amino-acid analysis of the natural brain-cortex peptide preparation Cortexin, as described in peer-reviewed Khavinson-group publications. Molecular weight is approximately 415 g/mol. The peptide is supplied as a lyophilized white-to-off-white powder, water-soluble, and stable under standard short-peptide storage conditions.
Mechanism of action.
The Khavinson framework hypothesises that short peptides cross cell membranes, reach nuclear chromatin, and modulate gene expression in tissue-specific patterns determined by the peptide sequence. Cortagen-specific published mechanistic work includes effects on heterochromatin organisation in aged cells and on gene expression in neural-tissue models. The framework remains theoretical relative to the receptor-pharmacology model used elsewhere in peptide research, and the strongest mechanistic data still comes from the Khavinson research network itself.
Research applications and the evidence base.
Published Cortagen research includes preclinical neural-tissue models and a notable line of work on peripheral nerve recovery, where Cortagen has been reported to produce structural and functional improvement in damaged peripheral nerve tissue in human pilot studies. The compound has been used in CNS-aging research, neural-regeneration models, and as a comparator in broader Khavinson-bioregulator screens. There are no completed Western Phase III human clinical trials, and the compound is not registered as a pharmaceutical in any major Western jurisdiction.
Research context.
Cortagen is the neural-tissue compound in the Khavinson family, sitting alongside Pinealon (also CNS, different sequence), Cerluten (also cortex-derived in some preparations), and Cortexin (the natural extract Cortagen was derived from). Researchers comparing Cortagen and Cortexin should note that Cortexin is a complex extract containing many peptides and proteins, while Cortagen is a single defined tetrapeptide — direct effect comparisons across the two should account for that compositional difference.
Storage and handling.
Lyophilized Cortagen should be kept refrigerated (2–8 °C) and protected from light. The peptide tolerates refrigerator-temperature storage reasonably well but does not tolerate repeated freeze-thaw cycles.
Quality and COA considerations.
A meaningful COA should confirm identity via mass spectrometry against the expected 415 g/mol molecular weight, purity by HPLC (≥98% benchmark), and explicit identification by sequence (Ala-Glu-Asp-Pro) — the same sequence is shared by several Khavinson studies under different abbreviations and labelling errors between Cortagen and similar tetrapeptides in this market are a known quality issue.
Research-use note: This monograph is an educational summary of the published research literature on Cortagen. The compound has not been evaluated in completed Western Phase III human clinical trials and is not approved for human use in any major jurisdiction known to VialTalk. Nothing here is medical advice or a usage recommendation.
